17,261 trials
Hepatitis B
Primary: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels in Currently Not Treated Population at Week 24 — -0.251; -0.096; -0.142; -0.203 log10 IU per…
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Heart Failure, Systolic
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3.1; 3.2 events/participant
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Change From Baseline in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) Composite Score at Week…
Familial ATTR-CM (ATTRm-CM, or FAC) · Wild-type ATTR-CM (ATTRwt-CM)
Primary: Change in Diastolic Blood Pressure — -3.1; -3.3; -4.3; -2.6 mm Hg
Infantile Hemangioma
Primary: Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls…
Multiple Myeloma · Diffuse Large B-Cell Lymphoma · Glioblastoma Multiforme
Primary: Part A: Number of Participants With Dose-limiting Toxicities — 0; 0; 1; 1 Participants
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Prostate Carcinoma Metastatic in the Bone
Primary: Progression-free Survival — 38.5 percentage of participants
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) at Week 12 — -15.8; -15.8; -17.5; -13.1 score on a scale
Lymphoma
Primary: Phase Ib: Percentage of Participants With Adverse Events (AEs) — 100; 100; 100; 100 percentage of participants
Acromegaly
Primary: Percent Change in Serum Insulin-like Growth Factor-1 (IGF-1) From Baseline to 28 Days After Last Dose — 8.9; -2.8; -7.5 percent change — p=0.306
Recurrent Plasma Cell Myeloma
Primary: Overall Response Percentage — 0.077 percentage of responders
Leptomeningeal Carcinomatosis
Primary: Percentage of Participants With Overall Survival — 44 percentage of participants
Sensorineural Hearing Loss
Primary: Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs) — 2; 3; 5; 6 Participants